ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
NASDAQ:ARQL opened at $4.96 on Friday. ArQule, Inc. has a 52-week low of $0.94 and a 52-week high of $5.29. The company has a debt-to-equity ratio of 1.50, a current ratio of 5.42 and a quick ratio of 5.42. The stock has a market cap of $451.69 million, a price-to-earnings ratio of -12.72 and a beta of 0.83.
Get ArQule alerts:ArQule (NASDAQ:ARQL) last released its quarterly earnings data on Monday, May 7th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The firm had revenue of $4.14 million during the quarter, compared to analysts’ expectations of $2.27 million. During the same period last year, the business posted ($0.11) earnings per share. equities research analysts predict that ArQule, Inc. will post -0.21 EPS for the current year.
Top Biotech Stocks To Watch For 2019: Kohl's Corporation(KSS)
Advisors' Opinion:- [By ]
It's a smart move. Instead of going more upscale to try and compete with the fancier boutiques, Macy's is now emulating the discount model that has served Kohl's Corp. (NYSE: KSS) and TJX Cos. (NYSE:TJX) so well.
- [By Rich Duprey]
This isn't even the first time Sears has paired itself with Amazon, agreeing last year to sell its Kenmore brand directly on the site. This put it on par with retailers like Best Buy, Calvin Klein, Chico's FAS, Kohl's (NYSE:KSS), and Nike in seeking to ride the e-tailer's coattails to higher sales.
- [By Logan Wallace]
Kohl’s (NYSE:KSS) had its target price increased by Morgan Stanley from $41.00 to $45.00 in a research report released on Wednesday morning. The brokerage currently has an underweight rating on the stock.
Top Biotech Stocks To Watch For 2019: Speedway Motorsports Inc.(TRK)
Advisors' Opinion:- [By Logan Wallace]
Truckcoin (TRK) is a PoW/PoS coin that uses the X11 hashing algorithm. Its genesis date was July 29th, 2014. Truckcoin’s total supply is 210,698,650 coins. Truckcoin’s official Twitter account is @truckcoin_v2 and its Facebook page is accessible here. Truckcoin’s official website is truckcoin.net.
- [By Money Morning Reports]
The company that popped up on our radar is Speedway Motorsports Inc. (NYSE: TRK).
Speedway Motorsports may not be a household name, but you've almost certainly heard of the venues it owns. Millions of people flock to its properties each year.
- [By Money Morning Staff Reports]
Speedway Motorsports Inc. (NYSE: TRK) owns eight of the premier tracks on the NASCAR circuit, including Charlotte Motor Speedway and the famed Bristol Motor Speedway.
- [By Joseph Griffin]
Truckcoin (TRK) is a PoW/PoS coin that uses the X11 hashing algorithm. It launched on July 29th, 2014. Truckcoin’s total supply is 201,189,260 coins. Truckcoin’s official Twitter account is @truckcoin_v2 and its Facebook page is accessible here. Truckcoin’s official website is truckcoin.net.
- [By Max Byerly]
Get a free copy of the Zacks research report on Speedway Motorsports (TRK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
ValuEngine lowered shares of Speedway Motorsports (NYSE:TRK) from a hold rating to a sell rating in a research note published on Tuesday.
Separately, Zacks Investment Research cut Speedway Motorsports from a hold rating to a sell rating in a research report on Thursday, April 12th.
Top Biotech Stocks To Watch For 2019: Liberty Global plc(LBTYB)
Advisors' Opinion:- [By Shane Hupp]
Liberty Global (NASDAQ:LBTYB) and Altice USA (NYSE:ATUS) are both large-cap consumer discretionary companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
No comments:
Post a Comment